Cite
CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.
MLA
Renzulli, Matteo, et al. “CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.” Blood, vol. 108, no. 11, Nov. 2006, p. 371. EBSCOhost, https://doi.org/10.1182/blood.V108.11.371.371.
APA
Renzulli, M., Terragna, C., Testoni, N., Montanari, E., Tosi, P., Zamagni, E., Tacchetti, P., Perrone, G., Martinelli, G., Baccarani, M., & Cavo, M. (2006). CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients. Blood, 108(11), 371. https://doi.org/10.1182/blood.V108.11.371.371
Chicago
Renzulli, Matteo, C. Terragna, N. Testoni, E. Montanari, P. Tosi, E. Zamagni, P. Tacchetti, et al. 2006. “CKS1B Over-Expression Significantly Predicts for a Lower Rate of Response to Primary Therapy with Thalidomide-Dexamethasone (Thali-Dex) for Newly Diagnosed Multiple Myeloma (MM) Patients.” Blood 108 (11): 371. doi:10.1182/blood.V108.11.371.371.